HBOT significantly lowered depression scores in post-stroke patients in a randomized sham-controlled trial (Tang 2026, n=61), and a 2026 meta-analysis of nine RCTs found a moderate reduction in depressive symptoms versus sham. The evidence is strongest when depression follows neurological injury. For primary major depression without a neurological trigger, the data is limited to small trials, indirect meta-analysis, and animal models.
From the author
Navigating chronic illness often involves dealing with mood changes that come from inflammation and fatigue, not just psychological factors. HBOT was one part of my broader protocol addressing neuroinflammation. I mention this because the line between “HBOT for depression” and “HBOT for the inflammatory cascade that contributes to depression” is important. Talk to your provider about the root cause, not just the symptom.
How Could HBOT Reduce Depression?
Depression is increasingly understood as more than a chemical imbalance. Neuroinflammation, impaired neuroplasticity, reduced cerebral blood flow, and mitochondrial dysfunction all play roles in depressive disorders. HBOT touches several of these pathways, which is why researchers have investigated it.
Neuroinflammation
Chronic low-grade brain inflammation is linked to depression, with elevated IL-6, TNF-alpha, and CRP consistently found in major depressive disorder. HBOT reduced inflammatory markers and depression-like behavior in a rat model of TBI-associated depression (Lim et al., 2017), providing a biological rationale for further study.3
BDNF and Neuroplasticity
Brain-derived neurotrophic factor (BDNF) supports neuron growth, survival, and repair, and tends to be low in depression. A 2026 sham-controlled trial by Tang and colleagues found that HBOT-driven increases in BDNF correlated directly with reductions in depression scores (r=0.66).1 In that trial, HBOT significantly reduced depression scores in post-stroke patients at both 2 and 4 weeks, with improvements tracking increased BDNF levels.
Cerebral Blood Flow and Mitochondrial Function
Neuroimaging shows reduced blood flow in specific regions in depression, particularly the prefrontal cortex. HBOT delivers oxygen at higher pressures, which can improve perfusion in oxygen-deprived tissue. There is also growing evidence that mitochondrial dysfunction contributes to depression, and the surplus of dissolved oxygen during HBOT may support cellular energy production in the brain. Both mechanisms are plausible but not yet confirmed as the drivers of any clinical benefit.
What Does the Research Say About HBOT for Depression?
The evidence is promising but still early, and it is strongest for depression secondary to neurological injury. Here is where the science stands.
Human Clinical Trials
The 2026 Tang randomized sham-controlled trial enrolled 61 patients with post-stroke depression (29 HBOT, 32 sham) in a double-blind design. HBOT produced significantly lower HAMD scores than sham at week 2 (p=0.017) and week 4 (p<0.001), with concurrent rises in serum BDNF and beta-NGF (p<0.01).1 A 2025 double-blind RCT in adults with persistent post-brain-injury symptoms found that 40 HBOT sessions produced greater symptom reduction than sham (mean difference 7.0, 95% CI 1.7 to 12.3, p=0.01) across cognitive, affective, and somatic domains, with a further course adding gains (Weaver 2025).4
A 2026 systematic review and meta-analysis by Al-Shamali and colleagues pooled 17 studies (n=920), with nine RCTs in the meta-analysis. For depressive symptoms, HBOT showed a large overall pooled effect (Cohen’s d = -0.82) but with high heterogeneity, and a clear dose-response: benefit at 2.0 ATA (d = -0.93) and none at 1.2 ATA. Against sham specifically, the effect was moderate (d = -0.68).2 The authors caution that estimates are heterogeneous and most studies are small.
HBOT for Depression by Population
| Population | Best study | Finding |
|---|---|---|
| Post-stroke depression | Tang 2026 RCT (n=61) | Significant HAMD reduction at 2 and 4 weeks |
| Post-brain-injury symptoms | Weaver 2025 double-blind RCT | Mean difference 7.0 across symptom domains |
| Primary major depression | No large dedicated trial | Insufficient; meta-analysis evidence is indirect |
What Is Still Missing
There are no large-scale, multi-center RCTs focused on HBOT for primary depression as the target condition. Most studies are small, and many enrolled patients whose depression was secondary to TBI, stroke, or chronic pain. The field needs larger trials with standardized protocols before HBOT can be recommended for depression with the confidence given to established therapies. For the broader picture, see our HBOT research overview.
How Does HBOT Compare to Standard Depression Treatments?
Standard care (cognitive behavioral therapy, SSRIs and SNRIs, exercise, and lifestyle interventions) is backed by decades of research and remains the foundation of depression treatment. HBOT is not a replacement for any of these, and no responsible practitioner would suggest stopping medication or therapy in favor of it. The realistic role is as a complementary approach, used alongside conventional treatment, particularly for people who have not responded adequately to first-line options. The trajectory may resemble ketamine and transcranial magnetic stimulation, which started with limited evidence and earned broader acceptance as data accumulated. HBOT is not there yet. For the full landscape, see our guide to HBOT for mental health and the more established research on HBOT for PTSD.
What Does an HBOT Protocol for Depression Look Like?
There is no standardized protocol, since the research is still evolving. The studies with positive results share some common parameters. You can learn more in our what to expect during treatment guide.
- Pressure: Most protocols use 1.5 to 2.0 ATA. The 2026 meta-analysis found benefit concentrated at 2.0 ATA and none at 1.2 ATA, so sub-therapeutic pressures may not help.
- Session duration: Typically 60 to 90 minutes of oxygen breathing per session.
- Frequency: Five sessions per week is the most common schedule.
- Total sessions: Studies used 20 to 60 sessions. A course of 30 to 40 is a reasonable starting point based on available data.
Because protocols are not standardized, work with a provider experienced in neurological applications and keep expectations realistic. Results in studies were measured after a full course, not after a handful of sessions.
Who Is Most Likely to Benefit From HBOT for Depression?
Based on the existing evidence, certain groups may be more likely to see benefit from HBOT as an adjunct.
Depression After Stroke or TBI
The strongest evidence comes from post-stroke and post-TBI populations, where depression is common and HBOT may address both the neurological injury and the mood symptoms.1 For primary major depression, the data are more limited and require further investigation.
Treatment-Resistant Depression
Roughly 30% of people with major depressive disorder do not reach full remission with standard antidepressants and therapy. For this group, adding an intervention such as HBOT may be worth exploring given its relatively favorable safety profile, though the direct evidence in treatment-resistant depression is still emerging.
Depression Linked to Chronic Illness
Conditions involving chronic inflammation and fatigue, such as Lyme disease, fibromyalgia, long COVID, and autoimmune disorders, frequently include depression. Since HBOT targets inflammation and oxygenation systemically, it may provide broader relief in these contexts, though this is inference from mechanism rather than dedicated trial data.
Who Should Be Cautious
HBOT is generally well tolerated but not risk-free. People with certain lung conditions, untreated pneumothorax, or specific ear and sinus issues may not be candidates. Review the potential side effects of HBOT and consult both your mental health provider and the HBOT clinic before starting.
Who Should Not Try HBOT
HBOT is generally safe under trained supervision, but not for everyone. The absolute contraindications are untreated pneumothorax (a collapsed lung, which pressure changes can make life-threatening) and certain drugs (bleomycin, cisplatin, doxorubicin, disulfiram). Relative contraindications, where a provider may modify or postpone treatment, include upper respiratory infection or sinus congestion, seizure disorder, COPD, high fever, prior ear surgery or chronic ear problems, claustrophobia, and pregnancy. Tell your physician if you use insulin or have an implanted device before starting.
Frequently Asked Questions
Can HBOT cure depression?
No. There is no evidence that HBOT cures depression. The trials to date indicate it may reduce symptoms in some people, particularly when used alongside conventional treatment and when depression follows a neurological injury. Depression is influenced by genetics, environment, psychology, and biology, and any treatment claiming to cure it outright should be viewed with skepticism.
How many HBOT sessions are needed for depression?
Clinical studies have used 20 to 60 sessions, with most positive results after 30 or more sessions at 1.5 to 2.0 ATA. This is not a one-session treatment. A realistic commitment is five sessions per week for four to eight weeks, followed by reassessment with your provider.
Is HBOT covered by insurance for depression?
In most cases, no. HBOT insurance in the United States generally covers HBOT only for FDA-approved indications such as non-healing wounds, carbon monoxide poisoning, and decompression sickness. Depression is not among them. Out-of-pocket costs for a full course range from $4,000 to $12,000 depending on provider and location. Some clinics offer package pricing or payment plans.
Sources
- Tang M, Zhao Y, Chen X, et al. Hyperbaric oxygen therapy upregulates neurotrophic factors to ameliorate post-stroke depression: a randomized sham-controlled trial. Neuropsychiatric Disease and Treatment. 2026. DOI: 10.2147/NDT.S573494.
- Al-Shamali HF, Shocker K, Thakkar J, et al. Effectiveness and safety of hyperbaric oxygen therapy for psychiatric disorders: a systematic review and meta-analysis. Psychiatry and Clinical Neurosciences. 2026. DOI: 10.1111/pcn.70077. PMID: 42169234.
- Lim SW, Wang CC, Wang YH, et al. Hyperbaric oxygen effects on depression-like behavior and neuroinflammation in traumatic brain injury rats. World Neurosurgery. 2017;100:128-137. DOI: 10.1016/j.wneu.2016.12.118.
- Weaver LK, Ziemnik R, Deru K, Russo AA. A double-blind randomized trial of hyperbaric oxygen for persistent symptoms after brain injury. Scientific Reports. 2025;15. DOI: 10.1038/s41598-025-86631-6. PMID: 40011516.
Medical Disclaimer
The content on BaricBoost.com is for informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.
Author
Seph Fontane Pennock is the founder of BaricBoost.com and Regenerated.com, a clinic directory for regenerative medicine serving 10,000+ providers across the United States. He previously built and sold PositivePsychology.com, which grew to 19 million users and became the largest evidence-based positive psychology resource on the web. Seph brings direct experience as an HBOT patient, having completed protocols at clinics across three continents while navigating mold illness, systemic inflammation, and autoimmune conditions. His treatment journey includes hyperbaric oxygen therapy, peptide protocols, NAD+ therapy, and consultations with specialists from Dubai to Cape Town to Mexico. This combination of entrepreneurial track record and lived patient experience shapes everything published on BaricBoost.com. Every article is grounded in peer-reviewed research, informed by real clinical encounters, and written for patients making high-stakes treatment decisions. Seph's focus is on bringing transparency, scientific rigor, and practical guidance to the hyperbaric oxygen therapy space.
